Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI
Not yet recruiting
University of Maryland
Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass
graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing
dialysis, the risk of dying is very high.There are no known therapies to reduce the chance of
developing kidney damage after heart surgery. There is evidence that patients with high
levels of a substance called ouabain have an increased risk of developing kidney damage. This
study is testing the hypothesis that giving a medication called DigiFab to lower the ouabain
levels will reduce the risk of developing kidney damage after heart surgery.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.